Modera Wealth Management LLC Purchases 7,590 Shares of AbbVie Inc. $ABBV

Modera Wealth Management LLC boosted its position in AbbVie Inc. (NYSE:ABBV) by 9.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 85,867 shares of the company’s stock after purchasing an additional 7,590 shares during the period. Modera Wealth Management LLC’s holdings in AbbVie were worth $22,462,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Arta Finance Wealth Management LLC increased its position in AbbVie by 8.9% in the 3rd quarter. Arta Finance Wealth Management LLC now owns 2,387 shares of the company’s stock valued at $621,000 after acquiring an additional 196 shares during the period. Whelan Financial raised its stake in shares of AbbVie by 15.6% during the third quarter. Whelan Financial now owns 1,962 shares of the company’s stock valued at $513,000 after acquiring an additional 265 shares during the last quarter. Prosperitas Financial LLC lifted its holdings in shares of AbbVie by 7.5% during the third quarter. Prosperitas Financial LLC now owns 23,977 shares of the company’s stock worth $6,272,000 after purchasing an additional 1,663 shares during the period. Brian Low Financial Group LLC lifted its holdings in shares of AbbVie by 4.3% during the third quarter. Brian Low Financial Group LLC now owns 9,147 shares of the company’s stock worth $2,393,000 after purchasing an additional 379 shares during the period. Finally, CHICAGO TRUST Co NA lifted its holdings in shares of AbbVie by 0.8% during the third quarter. CHICAGO TRUST Co NA now owns 55,681 shares of the company’s stock worth $14,566,000 after purchasing an additional 421 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.06% of the company’s stock.

AbbVie Stock Up 1.4%

ABBV opened at $294.80 on Friday. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $298.74. The company has a fifty day moving average of $269.35 and a 200-day moving average of $237.23. The stock has a market cap of $520.85 billion, a PE ratio of 83.28, a price-to-earnings-growth ratio of 1.33 and a beta of 0.24.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.73 by $0.09. The business had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.86 earnings per share. Sell-side analysts anticipate that AbbVie Inc. will post 13.92 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.3%. AbbVie’s dividend payout ratio (DPR) is 195.48%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

Wall Street Analyst Weigh In

Several analysts recently weighed in on ABBV shares. Canaccord Genuity Group boosted their price objective on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. BMO Capital Markets raised their target price on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Piper Sandler lifted their target price on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. The Goldman Sachs Group lifted their target price on AbbVie from $258.00 to $294.00 and gave the stock a “neutral” rating in a report on Friday, October 23rd. Finally, Citigroup upped their price target on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $279.86.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.